NASDAQ$HOLX

Hologic Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Hologic returned to top-line reported growth and exceeded guidance for both the top and bottom-line.

Hologic announced its financial results for the fiscal third quarter ended June 29, 2024, with revenue of $1,011.4 million, a 2.7% increase, and GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $1.06. The company's performance was driven by higher sales in Molecular Diagnostics, Breast Imaging, and Surgical.

  • Revenue of $1,011.4 million increased 2.7% for the quarter, or 3.1% in constant currency, primarily driven by higher sales in Molecular Diagnostics, Breast Imaging, and Surgical.
  • Excluding COVID-19 revenues, total organic revenue grew 5.5%, or 5.8% on a constant currency basis.
  • Cash flow from operations remained strong in the third quarter at $405.7 million.
  • Closed the acquisition of Endomagnetics on July 25, 2024, which develops and sells breast surgery localization and lymphatic tracing technologies.

Headline financials

Total Revenue

$1.01B

Previous: $984M+2.7%
EPS

$0.82

Previous: $0.93-11.8%
GAAP Gross Margin

55.4%

No prior period
Non-GAAP Gross Margin

61.1%

No prior period
Operating Margin

24.1%

No prior period
Non-GAAP Operating Margin

31.2%

No prior period
Net Margin

19.2%

No prior period
Non-GAAP Net Margin

24.8%

No prior period
Capital Expenditures

-$56M

Previous: $55.5M-200.9%
Free Cash Flow

$862M

Previous: $277M+210.9%
Net Income

$195M

Previous: -$40.5M+580.2%
Operating Income

$244M

Previous: $1.4M+17328.6%
Gross Profit

$560M

Previous: $368M+52.5%
Cash & Equivalents

$2.44B

Previous: $2.77B-11.8%
Total Assets

$8.89B

Previous: $9.34B-4.8%
R&D Expense

$64.1M

No prior period
Stock-Based Comp

$14.6M

Previous: $16.9M-13.6%

Revenue & EPS history

Hologic · Revenue · Quarterly

$1.01B

Q3 2024+2.7%vs Q3 2023
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Hologic · $769M total across 2 segments · Q4 2023

  • Diagnostics
    $416M-20.1%
  • Breast Health
    $353M+28.2%

Forward guidance

Hologic's financial guidance for the fourth quarter and full year 2024 is provided, incorporating Q3 performance, the addition of Endomagnetics, and the impact from the temporary stop-ship of Horizon DXA systems. The guidance is based on a full year non-GAAP tax rate of approximately 19.75%, and diluted shares outstanding of approximately 238 million for the full year.

Tailwinds

  • Fiscal 2024 Revenue between $4,012 - $4,027
  • Fiscal 2024 GAAP EPS between $3.37 - $3.44
  • Fiscal 2024 Non-GAAP EPS between $4.04 - $4.11
  • Q4 2024 Revenue between $970 - $985
  • Q4 2024 GAAP EPS between $0.80 - $0.87

Headwinds

  • Fiscal 2024 revenue is expected to have a (0.4%) to (0.1%) decrease
  • Constant Currency % Increase (Decrease) (0.5%) to (0.1%)
  • Organic excluding COVID-19 % Increase 5.2% to 5.6%
  • Q4 2024 GAAP EPS has an increase between 116.2% to 135.1%
  • Q4 2024 Non-GAAP EPS has an increase between 9.0% to 16.9%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro